Thomas N. Kakuda - Concepedia

Author

Thomas N. Kakuda

Also Known As

T Kakuda, T N Kakuda, T. Kakuda, T. N. Kakuda, TN Kakuda, Thomas Kakuda, Thomas N Kakuda, Thomas N. Kakuda, Thomas Naoki Kakuda, Thomas N. Kakuda

144

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Janssen (United States)University of Colorado Health University of Hong Kong University of Minnesota

About

Thomas N. Kakuda is an author at Janssen (Belgium) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	19	699
2	Hepatology	7	7	97
3	Epidemiology	2	2	25
4	Health Sciences	1	1	36
5	Global Health	1	1	23

Thomas N. Kakuda

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection Man‐Fung Yuen, Edward Gane, Dong Joon Kim, Gastroenterology	2019	149
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection Courtney V. Fletcher, Peter L. Anderson, Thomas N. Kakuda, AIDS	2002	147
Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Kees Brinkman, Thomas N. Kakuda Current Opinion in Infectious Diseases Mitochondrial DysfunctionImmunologyPharmacotherapyAntiviral DrugMitochondrial Biogenesis	2000	141
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals Peter L. Anderson, Thomas N. Kakuda, Sagar P. Kawle, AIDS	2003	137
6th International Workshop on Clinical Pharmacology of HIV Therapy Jennifer J. Kiser, Peter L. Anderson, Thomas N. Kakuda Expert Opinion on Pharmacotherapy Drug InteractionsTherapeutic Drug MonitoringTreatment And PreventionMedicineAntiviral Drug Development	2006	132
Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons Courtney V. Fletcher, Sagar P. Kawle, Thomas N. Kakuda, AIDS	2000	119
Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers Monika Schöller‐Gyüre, Thomas N. Kakuda, Vanitha Sekar, Antiviral Therapy	2007	98
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects Matt S. Anderson, Thomas N. Kakuda, William D. Hanley, Antimicrobial Agents and Chemotherapy Mg RaltegravirIntegrase Inhibitor RaltegravirHealthy SubjectsMedicineHuman Retrovirus	2008	79
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson, The Lancet. Gastroenterology & hepatology Ide AnaloguesViral HepatitisMedicineImmunologyAntiviral Drug Development	2023	64
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial Karen T. Tashima, Gordon Crofoot, Frank Tomaka, AIDS Research and Therapy	2014	63

Page 1